BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHERA (zanidatamab) Plus Chemo, With and Without TEVIMBRA (tislelizumab) Show Statistically Significant and Clinically Meaningful Improvement in Overall Survival Trastuzumab Plus Chemo for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at
BeOne's cancer medicine showed it helped people live longer when combined with chemotherapy, which is what doctors hope to see in testing. When a medicine hits these goals, it's a sign the company might have a real treatment to offer patients, so it's worth watching how doctors and the market react next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.